Breast cancer screening in women age 40-49
A canadian study shows that screening programs for women in
Menu
CDK4/6 inhibition with palbociclib, in combination with fulvestrant, trastuzumab and pertuzumab, triggers sustained senescence: new data from a Michelangelo Foundation study.
Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did not increase the rate of pathological complete remission, mostly influenced by PD-L1 expression.
NA-PHER2 trial, coordinated by Michelangelo Foundation, shows their efficacy as neoadjuvant therapy, with a relevant effect on Ki67
Lead by Michelangelo Foundation and Gianni Bonadonna Foundation’s experts, a review published on Nature Reviews – Clinical Oncology highlights the state of the art therapy in triple-negative breast cancer
A canadian study shows that screening programs for women in
A new study by the Michelangelo Foundation, in collaboration with
The phase 2 DAISY trial suggests that HER2 expression is
Oncotype DX helps to decrease discordancy in adjuvant chemotherapy recommendations
Among selected patients with previous hormone receptor–positive early breast cancer,
PROTAC, a new MDM2-targeted degrader, kills p53-inactivated triple negative breast
Compared with physician’s choice treatment, trastuzumab deruxtecan shows a favorable
Anthracycline plus taxane regimens are among the most efficacious at
The GELATO trial shows the feasibility of trials specifically designed
Patients with HER2-positive early breast cancer who achieve a pathologic
ctDNA and residual cancer burden after neoadjuvant systemic therapy are
The effects of omission of radiotherapy after surgery on local
Enrollment of patients with HER2+ metastatic breast cancer and PIK3CA
Olaparib significantly prolonged progression-free survival compared to chemotherapy, particularly in
This multicentric machine learning model improves performance of local models
Foundation’s experts and data in key educational sessions to share
Lead by Michelangelo Foundation and Gianni Bonadonna Foundation’s experts, a
NA-PHER2 trial, coordinated by Michelangelo Foundation, shows their efficacy as
Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did
CDK4/6 inhibition with palbociclib, in combination with fulvestrant, trastuzumab and
CDK4/6 inhibition with palbociclib, in combination with fulvestrant, trastuzumab and
Atezolizumab added to nab-paclitaxel and carboplatin as neoadjuvant therapy did
NA-PHER2 trial, coordinated by Michelangelo Foundation, shows their efficacy as
Lead by Michelangelo Foundation and Gianni Bonadonna Foundation’s experts, a
Foundation’s experts and data in key educational sessions to share
This multicentric machine learning model improves performance of local models
